Dejan Micic to Disease Progression
This is a "connection" page, showing publications Dejan Micic has written about Disease Progression.
Connection Strength
0.052
-
Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease. Aliment Pharmacol Ther. 2018 Mar; 47(6):753-762.
Score: 0.028
-
Predicting Outcomes to Optimize Disease Management in Inflammatory Bowel Diseases. J Crohns Colitis. 2016 Dec; 10(12):1385-1394.
Score: 0.025